Targeted Pyroptosis with Resveratrol Nanoparticles to Reduce Secondary Brain Injury and Post-Traumatic Epilepsy

Area of Science:

• Neuroscience
• Biotechnology
• Pharmacology

Background:

• Traumatic brain injury (TBI) causes high mortality and disability, often leading to post-traumatic epilepsy (PTE).
• Secondary brain damage, driven by neuroinflammation and pyroptosis, exacerbates TBI outcomes and epilepsy development.
• Current TBI treatments struggle to address secondary damage due to the blood-brain barrier (BBB) limiting drug delivery.

Purpose of the Study:

• To develop an enhanced drug delivery system for resveratrol (RV) to target brain injury.
• To investigate the efficacy of a novel nanoliposome (C-Lips/RV) in mitigating pyroptosis and inflammation post-TBI.
• To evaluate the therapeutic potential of C-Lips/RV in reducing post-traumatic epilepsy and improving functional recovery.

Main Methods:

• Engineered cysteine-alanine-glutamine-lysine peptide-modified nanoliposomes loaded with resveratrol (C-Lips/RV).
• Administered C-Lips/RV to a rat model of TBI.
• Assessed RV pharmacokinetics, brain targeting, pyroptosis markers, PTE incidence, secondary damage progression, and functional recovery.

Main Results:

• C-Lips/RV exhibited a prolonged half-life and effective accumulation in the injured brain tissue.
• Treatment with C-Lips/RV significantly reduced pyroptosis and neuroinflammation.
• C-Lips/RV administration led to a decrease in PTE development, slowed secondary damage, and improved neurological function.

Conclusions:

• C-Lips/RV represents a promising strategy for enhancing TBI therapy by overcoming BBB limitations.
• Targeted delivery of resveratrol via C-Lips/RV effectively mitigates pyroptosis and reduces the risk of PTE.
• This approach offers a potential new avenue for managing secondary brain injury and its sequelae.